Atezolizumab Clinical Trials

111 actively recruiting trials across 41 locations

Also known as: 1380723-44-3, Atezolizumab (Tecentriq, ATEZOLIZUMAB), Immunoglobulin G1, Anti-CD274 mAb (MPDL3280A), RG7446, RO5541267, Alectinib, Atezolizumab combined with bevacizumab, Ceritinib, Dostarlimab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, Niraparib, Phesgo (trastuzumab og pertuzumab), Pirfenidone, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, TECENTRIQ, TECENTRIQ®, Tecentriq, Tecentriq; RO5541267, Tecentriq®, Vemurafenib and cobemitinib, entrectinib, humanized IgG1 monoclonal antibody against PD-L1, vismodegib

Filter by location:

Other33 trials

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

Phase 1/2

A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)

Phase 2

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

Phase 3

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

Phase 1/2

A Study on the Efficacy of Atezolizumab Combined with Chemotherapy

A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB

Phase 2

Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma

Phase 2

Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).

Phase 2

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Phase 2/3

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Phase 2/3

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

Phase 4

Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Phase 2

FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

Phase 3

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

Phase 2

Improving Public Cancer Care by Implementing Precision Medicine in Norway

Phase 2

Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma

Phase 1/2

Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

Phase 2

KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients

Phase 1

NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial

Phase 2

Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer

Phase 2

Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)

Phase 2

Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer

Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma

Phase 4

ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

Phase 2

Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc)

Phase 2

Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

Phase 1/2

Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo

Phase 2

Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

Phase 3

The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

Phase 3

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

Phase 2

Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients

Phase 2

Birmingham, Alabama8 trials

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

UAB Comprehensive Cancer Center

Phase 1

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

University of Alabama -Birmingham

Phase 1/2

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

The Kirklin Clinic of University of Alabama Birmingham Hospital

Phase 1/2

A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC

University of Alabama at Birmingham

Phase 1/2

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

University of Alabama at Birmingham (UAB)

Phase 1

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

University of Alabama at Birmingham Cancer Center

Phase 3

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

University of Alabama at Birmingham Cancer Center

Phase 2/3

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

University of Alabama at Birmingham Cancer Center

Phase 2/3

Houston, Texas8 trials

A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors

MD Anderson Cancer Center

Phase 1

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria

Houston Methodist Research Institute

Phase 4

Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study

M D Anderson Cancer Center

Phase 2

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

M D Anderson Cancer Center

Phase 1/2

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

M D Anderson Cancer Center

Phase 1/2

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

M D Anderson Cancer Center

Phase 2

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

M D Anderson Cancer Center

Phase 1

SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma

The University of Texas M. D. Anderson Cancer Center

Phase 2

Duarte, California7 trials

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

City of Hope

Phase 1/2

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

City of Hope

Phase 1/2

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

City of Hope Comprehensive Cancer Center

Phase 2

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Phase 1/2

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

Zai Lab Site 2005

Phase 1

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

City of Hope /ID# 261468

Phase 2/3

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

City of Hope Comprehensive Cancer Center

Phase 1/2

San Francisco, California5 trials

A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial

University of California, San Francisco

Phase 2

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Stanford University

Phase 1

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

University of California San Francisco

Phase 2

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

University of California, San Francisco

Phase 2

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

University of San Francisco, California

Phase 2

Los Angeles, California4 trials

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

USC Norris Comprehensive Cancer Center

Phase 2

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Local Institution - 0070

Phase 1/2

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

Research Facility

Phase 1

Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial

Keck Medicine of USC Koreatown

Phase 2

Phoenix, Arizona3 trials

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

St. Joseph's Hospital and Medical Center

Phase 3

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Research Site

Phase 3

Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors

Mayo Clinic Hospital

Phase 1/2

Atlanta, Georgia3 trials

Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma

Chilldren's Healthcare of Atlanta

Phase 1

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

Emory University Hospital Midtown

Phase 2

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Winship Cancer Institute at Emory University

Phase 2

Daphne, Alabama2 trials

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Southern Cancer Center, PC

Phase 3

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Southern Cancer Center

Phase 2

La Jolla, California2 trials

A Study Evaluating Single-agent Inavolisib and Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers

Moores Cancer Center at UC San Diego Health

Phase 1

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

UC San Diego Moores Cancer Center

Phase 2

Washington D.C., District of Columbia2 trials

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Johns Hopkins University: Sibley Memorial Hospital

Phase 2

Evaluating Novel Therapies in ctDNA Positive GI Cancers

Georgetown Lombardi Comprehensive Cancer Center

Phase 3

Chicago, Illinois2 trials

Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

University of Illinois Cancer Center

Phase 2

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

Ann & Robert H. Lurie Children's Hospital of Chicago

Phase 1/2

Bethesda, Maryland2 trials

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

National Institutes of Health Clinical Center

Phase 1

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

National Institutes of Health Clinical Center

Phase 2

Nashville, Tennessee2 trials

Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation

Vanderbilt University/Ingram Cancer Center

Phase 1/2

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Vanderbilt University/Ingram Cancer Center

Phase 1/2

Scottsdale, Arizona1 trial

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Mayo Clinic in Arizona

Phase 2

Tucson, Arizona1 trial

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

University of Arizona Cancer Center

Phase 2

Springdale, Arkansas1 trial

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

Highlands Oncology Group

Phase 2/3

Berkeley, California1 trial

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

Alta Bates Summit Medical Center-Herrick Campus

Phase 3

Beverly Hills, California1 trial

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Beverly Hills Cancer Center

Phase 2

Costa Mesa, California1 trial

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

UC Irvine Medical Center

Phase 1/2

Fresno, California1 trial

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

ClinRé 001-022 (Premier Cancer Care and Infusion Center)

Phase 3

Irvine, California1 trial

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

City of Hope Orange County Lennar Foundation Cancer Center

Phase 1

Sacramento, California1 trial

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

University of California Davis

Phase 2

Stanford, California1 trial

A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)

GSK Investigational Site

Phase 1

Lone Tree, Colorado1 trial

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

Rocky Mountain Cancer Centers, LLP

Phase 1/2

New Haven, Connecticut1 trial

Iadademstat + SBRT With Atezo in ES-SCLC

Yale University

Phase 1

Clermont, Florida1 trial

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Clermont Oncology Center

Phase 3

Ocala, Florida1 trial

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

Ocala Oncology Center /ID# 278269

Phase 2

Fairway, Kansas1 trial

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

The University of Kansas Cancer Center (KUCC)

Phase 1/2

Baltimore, Maryland1 trial

An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery

Mercy Medical Center - Medline Healthcare Services LLC

Detroit, Michigan1 trial

SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer

Henry Ford Cancer- Detroit

Phase 2

Rochester, Minnesota1 trial

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Mayo Clinic in Rochester

Phase 1/2

Basking Ridge, New Jersey1 trial

A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 1

Buffalo, New York1 trial

Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

Roswell Park Cancer Institute

Phase 2

New York, New York1 trial

Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant

Icahn School of Medicine at Mount Sinai

Phase 4

Chapel Hill, North Carolina1 trial

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Lineberger Comprehensive Cancer Center

Phase 1

Columbus, Ohio1 trial

Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Ohio State University Comprehensive Cancer Center

Phase 1

Philadelphia, Pennsylvania1 trial

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Abramson Cancer Center of the University of Pennsylvania

Phase 1/2

Pittsburgh, Pennsylvania1 trial

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

UPMC Hillman Cancer Center

Phase 2

Memphis, Tennessee1 trial

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

St. Jude Children's Research Hospital

Phase 1/2

Salt Lake City, Utah1 trial

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Huntsman Cancer Institute/University of Utah

Phase 2

Fairfax, Virginia1 trial

The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

Inova Schar Cancer Institute - Fair Oaks

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.